Deregulation of the PI3K signaling pathway is observed in many human cancers and occurs most frequently through loss of PTEN phosphatase tumor suppressor function or through somatic activating mutations in the Class IA PI3K, PIK3CA. Tumors harboring activated p110α, the protein product of PIK3CA, require p110α activity for growth and survival and hence are expected to be responsive to inhibitors of its lipid kinase activity. Whether PTEN-deficient cancers similarly depend on p110α activity to sustain activation of the PI3K pathway has been unclear. In this study, we used a single-vector lentiviral inducible shRNA system to selectively inactivate the three Class IA PI3Ks, PIK3CA, PIK3CB, and PIK3CD, to determine which PI3K isoforms are responsible for driving the abnormal proliferation of PTEN-deficient cancers. Down-regulation of PIK3CA in colorectal cancer cells harboring mutations in PIK3CA inhibited downstream PI3K signaling and cell growth. Surprisingly, PIK3CA depletion affected neither PI3 signaling nor cell growth in 3 PTEN-deficient cancer cell lines. In contrast, down-regulation of the PIK3CB isoform, which encodes p110β, resulted in pathway inactivation and subsequent inhibition of growth in both cell-based and in vivo settings. This essential function of PIK3CB in PTEN-deficient cancer cells required its lipid kinase activity. Our findings demonstrate that although p110α activation is required to sustain the proliferation of established PIK3CA-mutant tumors, PTEN-deficient tumors are dependent instead on p110β signaling. This unexpected finding demonstrates the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response.

The PI3K signaling pathway is a critical regulator of many cellular processes that promote the transformation of a normal cell to a cancer cell. Initiation of this signaling cascade commences with the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to produce phosphatidylinositol 3,4,5-trisphosphate (PIP3), which results in cell proliferation, motility, and survival, among many other cellular changes (1). Cellular phosphatidylinositol 3,4,5-trisphosphate levels are regulated tightly by the opposing activities of the lipid phosphatase PTEN and the lipid kinase activity of Class IA PI3Ks (2). PTEN inactivation disrupts this balanced reaction and leads to deregulated cell growth (3–5). Consequently, the finding that PTEN frequently is inactivated in many tumors provided the first direct evidence linking the PI3K pathway to the etiology of human cancers (6–8). In addition, recent sequencing analyses revealed that one of the Class IA PI3K isoforms, PIK3CA, is frequently activated through somatic mutations in many cancers (9–14). The observation that PTEN loss and PIK3CA somatic activating mutations occur in most human tumors in a mutually exclusive fashion strongly indicates that hyperactivation of the PI3K pathway is an essential driver of tumorigenesis (15–19).

Growing evidence supporting the dependency of cancer cells on deregulated PI3K pathway activity for survival has resulted in considerable efforts directed at developing pharmacological inhibitors to stem aberrant PI3K signaling in tumors (20). So far, the challenges of restoring the activity of loss-of-function mutations characteristic of tumor suppressors have precluded PTEN as a viable target for drug discovery. On the other hand, recent successes in developing small-molecule inhibitors against activated kinases have spurred considerable interest in PI3Ks as targets for anticancer drugs (21, 22). Of particular interest are the Class IA PI3Ks, which encompass the three p110 lipid kinase subunits, p110α, p110β, and p110δ, because they are primarily responsible for phosphorylating the critical signaling molecule, PIP2 (23). First-generation pan-PI3K inhibitors target all 3 Class IA isoforms (24, 25). Even though Class IA isoforms share many structural and regulatory similarities, the increasing biological understanding of these lipid kinases indicates that they have nonredundant cellular functions (26–29). Thus, concerns about unnecessary isoform-derived on-target toxicities of pan-PI3K inhibitors have directed considerable efforts toward the development of isoform-selective inhibitors (30).

Although it generally is accepted that somatic activating mutations in PIK3CA are important for tumorigenesis, it has not yet been demonstrated formally that aberrant p110α activity is required to maintain the transformed phenotype in established tumors. Furthermore, it remains unclear whether p110α activity, either alone or in combination with other Class IA lipid kinases, drives cell growth and survival in PTEN-deficient cancers. To clarify the role of p110α in the maintenance of PIK3CA-mutant cells and to identify the Class IA lipid kinase required to drive PI3K pathway signaling in PTEN-deficient tumors, we have generated a single-vector inducible shRNA system to inactivate individual Class IA PI3K isoforms potently and selectively in a panel of cancer cell lines. PIK3CA depletion in 2 colorectal cancer cell lines, HCT116 and DLD1, each harboring a unique hotspot mutation in PIK3CA, resulted in reduced proliferation, colony formation, and soft agar growth and strongly inhibited downstream pathway signaling. Importantly, RNAi-mediated depletion of PIK3CA in HCT116 tumor xenografts resulted in tumor growth retardation, providing direct evidence that inactivation of PIK3CA in an established tumor setting leads to inhibition of tumor growth. In contrast, we surprisingly found that depletion of PIK3CA does not affect signaling through the PI3K pathway in the PTEN-deficient cancer cell lines PC3, BT549, and U87MG, nor does it impact their transformed phenotypes. Instead, down-regulation of PIK3CB resulted in strong inhibition of growth and PI3K pathway signaling in all PTEN-deficient cell lines tested. We further demonstrate that the lipid kinase activity of p110β is required to sustain PI3K signaling in PTEN-deficient cancer cells, providing a strong rationale for the development of p110β-specific inhibitors for the treatment of PTEN-deficient cancers.

Author contributions: S.W., D.W., and C.L. designed research; S.W., D.W., S.-M.M., A.L., C.M., and R.d.B. performed research; S.W., D.W., S.-M.M., A.L., F.S., Y.-M.Y., and C.L. analyzed data; and S.W., D.W., F.S., and C.L. wrote the paper.

Conflict of interest statement: All authors are employees of the Novartis Institutes for BioMedical Research.

This article is a PNAS Direct Submission.

© 2008 by The National Academy of Sciences of the USA
Results

PIK3CA Depletion Results in Suppression of Downstream PI3K Signaling and Leads to Growth Inhibition of Colon Cancer Cell Lines with PIK3CA Mutations. To assess accurately the dependency of tumors on PIK3CA for both initiation and maintenance of the tumorigenic phenotype, we developed a single-vector lentiviral doxycycline-inducible shRNA system that allows efficient and regulatable target gene knockdown in multiple cell lines [supporting information (SI) Fig. S1]. Two human colorectal cancer cell lines, HCT116 and DLD1, were stably transduced with the inducible vector containing either scrambled control sequence or shRNA targeting PIK3CA. In the absence of doxycycline, the levels of PIK3CA mRNA and protein product were similar in both the control shRNA-expressing cells and the PIK3CA shRNA-expressing cells. In sharp contrast, the addition of doxycycline resulted in a dramatic down-regulation of PIK3CA mRNA (> 90% knockdown) (Fig. L4) and concurrent reduction in p110α protein levels (Fig. 1B) only in the cells expressing PIK3CA shRNA. No measurable off-target effects on other Class IA PI3K isoforms were observed as determined by quantitative RT-PCR (data not shown).

We next determined the contribution of PIK3CA to the tumorigenic phenotype in the colorectal cancer cell lines HCT116 and DLD1. HCT116 has an H1047R mutation in exon 20 (kinase domain), whereas DLD1 contains an E545K alteration in exon 9 (helical domain) (31). Because it is well accepted that the p110α mitogenic signal is propagated through a number of well-characterized downstream targets, we hypothesized that inducible knockdown of PIK3CA would alter the phosphorylation state of key p110α effector proteins. Indeed, down-regulation of PIK3CA was accompanied by substantial reduction in phospho-AKT, phospho-FOXO, phospho-PRAS40, and phospho-S6 in both cell lines (Fig. 1B). To assess phenotypic consequences of PIK3CA knockdown, we studied the proliferation of stable shRNA cell lines in the absence or presence of doxycycline under full (10%) (data not shown) or reduced (0.5%) serum conditions over a 10-day period. Proliferation of cells containing shRNA targeting PIK3CA in the absence of doxycycline was indistinguishable from the control shRNA-expressing cells. Depletion of PIK3CA in both HCT116 and DLD1 lines significantly decreased growth under all conditions studied (Fig. 1C). PIK3CA knockdown also strongly impaired the ability of colorectal cancer cells to survive and grow when plated at low density (Fig. 1D). Finally, anchorage-independent growth of HCT116 cells, a hallmark of the transformed phenotype, also was suppressed by PIK3CA depletion (Fig. 1E). Consistent with previously published results, silencing of PIK3CA in HCT116 cells resulted in poly(ADP ribose) polymerase cleavage, suggestive of increased levels of apoptosis, and prolonged G1 phase of the cell cycle as determined by FACS analysis (data not shown). These data are consistent with earlier findings that colorectal cancer cell lines containing mutations in PIK3CA are dependent on p110α for proliferation and survival (31).

Down-Regulation of PIK3CA in PTEN-Deficient Cancer Cell Lines Affects Neither Signaling Through the PI3K Pathway nor Cell Growth and Survival. Most cancers with deregulated PI3K signaling have acquired either an activating mutation in PIK3CA or an inactivating mutation in the opposing lipid phosphatase PTEN. To investigate whether the increase in signaling through the PI3K pathway in PTEN-deficient cell lines depends on p110α lipid kinase activity, we introduced the inducible shRNA targeting PIK3CA into PC3, U87MG, and BT549, which were confirmed to be PTEN deficient (Fig. S2A). These cancer cell lines represent the major cancer types with a high frequency of PTEN inactivation, namely prostate cancer (30%–50%) (32), brain cancer (>30%) (33), and breast cancer (20%) (34). Greater than 90% knockdown of PIK3CA mRNA was achieved in PC3 and BT549 cell lines, whereas ~80% knockdown

Fig. 1. PIK3CA is required for PI3K signaling and growth in p110α-mutant cell lines. Dox = doxycycline. (A) HCT116 and DLD1 colorectal cancer cell lines transduced with scramble control or PIK3CA-inducible shRNA were cultured in the presence or absence of doxycycline at 10 ng/ml for 72 h and harvested for Taqman analysis. PIK3CA mRNA levels in the control samples (– DOX) were set to 100%. (B) Similarly treated cells were analyzed by Western blot to monitor changes in PI3K pathway signaling. The phosphorylation states of PRAS40 at Thr-246, Foxo1 at Thr-24, Foxo3a at Thr-32, and p70/S6K at Thr-389 were assessed. Endogenous GAPDH is shown as a loading control. (C) Proliferation of stable HCT116 and DLD1 shRNA cell lines under low (0.5% FBS) serum conditions in the presence or absence of doxycycline (10 ng/ml) were monitored using CellTiterGlo over a 10-day period. Results are shown as mean ± SE of 3 replicates. (D) Cells cultured in a 6-well dish for 14 days in the presence (10 ng/ml) or absence of doxycycline were stained with crystal violet to visualize colony growth. All experiments were done in triplicates. (E) HCT116 cells were grown in semisolid medium for 14 days in the presence (100 ng/ml) or absence of doxycycline. Colonies were visualized by Hoechst 33342 staining and photographed using a Nikon fluorescence microscope. Colonies were counted (mean ± SE, in triplicate) using ImagePro software.
was observed in U87MG upon shRNA induction (Fig. 2A). Correspondingly, a strong reduction in p110α protein levels was observed by Western analysis in all 3 lines (Fig. 2B). In contrast to HCT116 and DLD1 cells, however, the levels of the major downstream PI3K pathway effector, phospho-AKT, were not affected by PIK3CA depletion in all PTEN-deficient cell lines tested (Fig. 2B). The differential response to PIK3CA silencing could not be explained by gross differences in PIK3CA expression levels (Fig. S2B) or PIK3CA-knockdown efficiencies (Fig. S2C).

Consistent with the unperturbed PI3K downstream signaling, depletion of PIK3CA in PTEN-deficient cell lines also did not affect cell proliferation (Fig. 2C). Because of the high frequency of PTEN deletions found in prostate cancer, we focused on PC3 cell line to further examine the role of PIK3CA depletion in PTEN-deficient cells. In a clonogenic survival assay, the down-regulation of PIK3CA in PC3 stable cells did not affect colony size or number in comparison to the doxycycline-un-treated cells (Fig. 2D). Furthermore, PIK3CA down-regulation did not affect the soft agar growth of PC3 cells (Fig. 2E).

**PIK3CA Depletion Inhibits Phospho-AKT and Tumor Growth in HCT116 but not in PC3 Xenografts.** To address the dependency of both PIK3CA-mutant and PTEN-deficient cells on PIK3CA in an *in vivo* setting, we next assessed the effect of inducible silencing of PIK3CA in tumor xenograft models. Although somatic cell knockout experiments demonstrated that PIK3CA is important for the proliferation of PIK3CA-mutant tumors (31), these experiments could not distinguish between its role in tumor initiation versus maintenance. Using our inducible knockdown system, we therefore sought to determine if p110α activity also is required for the maintenance of established tumors. HCT116 cells stably expressing inducible shRNA targeting PIK3CA were implanted into nude mice and allowed to establish as tumor xenografts. Once tumor volume exceeded 100 mm³, doxycycline or vehicle was administered to tumor-bearing animals either continuously in drinking water or once a day via oral gavage. Doxycycline treatment resulted in significant inhibition of HCT116-PIK3CA shRNA tumor growth (the mean increase of tumor volumes of treated animals divided by the mean increase of tumor volumes of control animals multiplied by 100 [%] < 50%, *p < 0.05*) (Fig. 3A) but had no effect on the growth of wild-type HCT116 xenografts or mouse body weight regardless of the administration route (data not shown). To confirm the knockdown of endogenous p110α levels and to assess its effect on downstream PI3K signaling, tumor xenografts samples were analyzed at the end of the study. PIK3CA protein levels were reduced dramatically in doxycycline-treated tumors compared with their vehicle-treated counterparts (Fig. 3C). Furthermore, PIK3CA down-regulation was accompanied by the suppression of phospho-AKT, its direct downstream substrate phospho-PRAS40, and its indirect target phospho-S6 (Fig. 3C).

In striking contrast, shRNA-mediated inhibition of PIK3CA did not affect the growth of PC3 PTEN-deficient tumor xenografts (Fig. 3B), despite significant down-regulation of p110α levels (Fig. 3C). Consistent with the results from cell-based assays, knockdown of PIK3CA did not alter downstream PI3K signaling, tumor xenografts samples were analyzed at the end of the study. PIK3CA protein levels were reduced dramatically in doxycycline-treated tumors compared with their vehicle-treated counterparts (Fig. 3C). Furthermore, PIK3CA down-regulation was accompanied by the suppression of phospho-AKT, its direct downstream substrate phospho-PRAS40, and its indirect target phospho-S6 (Fig. 3C).

**p110α Is Dispensable for the Maintenance of PI3K Signaling in the Absence of PTEN.** To confirm further that p110α is dispensable to the maintenance of PI3K signaling in the absence of PTEN, we tested...
if inactivation of PTEN would render PIK3CA-mutated cells p110α independent. HCT116 cells stably expressing inducible shRNA targeting PIK3CA were transfected transiently with either control or PTEN siRNA and were incubated in the absence or presence of doxycycline. Interestingly, we observed that, even in the presence of an activating PIK3CA mutation, loss of PTEN alone was able to further increase signaling through the PI3K pathway (Fig. 4A; compare lanes 3, 4, and 7 with lanes 1, 2, and 5). More importantly, although knockdown of PIK3CA alone resulted in a dramatic reduction of phospho-AKT levels (Fig. 4A; compare lane 6 with lanes 1, 2, and 5), the double knockdown of both PTEN and PIK3CA fully restored the phosphorylation of AKT (Fig. 4A; compare lane 8 with lanes 1, 2, and 5). This finding further demonstrates that the activation of the PI3K pathway resulting from PTEN loss does not depend on p110α activity.

**PTEN-Deficient Cells Depend on PIK3CB for Signaling and Cell Growth.** The finding that phospho-AKT levels are not perturbed after PIK3CA depletion in the genetic context of PTEN deficiency suggested that PI3K signaling may be mediated by other PI3K isoforms. We therefore introduced inducible shRNAs targeting the 2 remaining Class IA PI3Ks, PIK3CB and PIK3CD, into the 3 PTEN-deficient cell lines BT549, PC3, and U87MG. Whereas knockdown of PIK3CD did not affect signaling in any of the 3 PTEN-deficient lines tested (data not shown), depletion of PIK3CB (Fig. 4B) resulted in striking inhibition of growth in these cell lines (Fig. 4C). Importantly, an independent shRNA targeting a different region of the PIK3CB transcript similarly inhibited growth of PC3 cells in a clonogenic survival assay (Fig. S3).

To directly test whether the lipid kinase activity of p110β is required for the survival of PTEN-deficient cancer cells, we used an shRNA-rescue strategy. Wild-type PIK3CB cDNA was modified to contain 6 synonymous mutations in the shRNA targeting region and expressed using a doxycycline-regulated lentiviral vector system (Fig. S1). In addition, an shRNA-resistant lipid kinase–dead mutant, p110βD937A, was generated by converting the ATP-binding DFG motif to AFG. The expression levels of both shRNA-resistant p110β rescue constructs were similar to the endogenous level (Fig. 5A) and did not affect the growth or signaling in PC3 cells expressing control shRNA (Fig. S4A–C). Re-expression of wild-type p110β, but not its kinase-dead counterpart, restored both PI3K pathway signaling and cell growth (Fig. 5B and C) in PC3 cells depleted for endogenous PIK3CB. These data indicate that PTEN-deficient cells specifically require p110β lipid kinase activity to sustain PI3K pathway signaling and abnormal cell proliferation.

**p110β-Specific Compounds Inhibit Signaling and Cell Growth in PTEN-Deficient Cells but not in PIK3CA-Mutant Cells.** The recent development of isoform-selective compounds allowed us to test whether small-molecular-weight inhibitors can recapitulate our genetic findings, which predict that PTEN-deficient and p110α-mutant cells would exhibit different sensitivities to isoform-specific Class IA PI3K inhibitors. As expected, treatment of all cell lines with the pan-PI3K inhibitor, BEZ235 (24), reduced phospho-AKT levels (Fig. S5A). Strikingly, the p110β-selective inhibitor TGX221 (26) inhibited phospho-AKT levels only in PTEN-deficient cells (Fig. S5A), fully consistent with our results using the isoform-selective inducible shRNAs. Similar results were obtained in a recent study using the same p110β compound in a panel of breast cancer cell lines (35). The p110β-specific inhibitor IC87114 (36), however, did

![Figure 3](image-url)

**Fig. 3.** PIK3CA is required for growth of p110α mutant, but not PTEN-deficient, tumors in vivo. Dox = doxycycline. (A and B) HCT116 and PC3 cells stably transduced with PIK3CA inducible shRNA were implanted into nude mice as described in Materials and Methods. Mice containing tumors of at least 100 mm³ were administered vehicle control or doxycycline either freely in drinking water (ad libitum) or once a day (q.d.) by oral gavage (p.o.). Tumor volume was monitored by caliperizing (mean ± SEM). (C) Changes in PI3K signaling in tumor xenografts were assessed by Western blot using indicated antibodies. Phosphorylation states of PRAS40 at Thr 246 and S6 at Ser-235/S236 were assessed.

![Figure 4](image-url)

**Fig. 4.** PTEN-deficient cells require PIK3CB for growth. Dox = doxycycline. (A) Stable control or PIK3CA shRNA–containing HCT116 cells were transfected with either control or PTEN siRNA. Cells grown in the absence or presence of doxycycline were harvested for Western blot analysis after 72 h of treatment. (B) BT549, PC3, and U87MG cells stably transduced with either scramble control or PIK3CB were grown in the presence or absence of doxycycline for 72 h. PIK3CB transcript levels were assessed at the end of treatment by Taqman RT-PCR. (C) Described cells were cultured in a 6-well dish in the presence or absence of doxycycline (10 ng/ml) for 14 days. The effects of PIK3CB silencing on foci formation were visualized by crystal violet staining.
Fig. 5. p110β-Lipid kinase activity is required for PI3K pathway signaling and growth in PTEN-deficient cells. Stable PC3 cells containing inducible PIK3CB targeting shRNA were transduced with either wild-type or kinase-dead (D937A) shRNA-resistant p110β cDNA. Dox – doxycycline. (A) PIK3CB transcript levels were assessed by Taqman analysis in the absence or presence of 10 ng/ml of doxycycline treatment for 72 h. (B) The effect on PI3K pathway signaling was assessed by Western blot analysis upon expression of the respective rescue construct for 96 h. The effect on PRAS40 phosphorylation at Thr 246 was determined. (C) Stable PC3 cells containing the respective rescue constructs were cultured in a 6-well dish for 14 days in the presence (10 ng/ml) or absence of doxycycline. Cells were stained with crystal violet to visualize colony growth. All experiments were done in triplicate.

Inactivation of PIK3CB Inhibits Growth and PI3K Pathway Signaling in a PTEN-Deficient Tumor Xenograft Model. To determine the functional consequences of PIK3CB inactivation in a tumor setting, PC3 cells containing the inducible shRNA targeting PIK3CB were implanted into nude mice. As described earlier, tumors were allowed to reach at least 100 mm³ before administration of either doxycycline or vehicle control by oral gavage. Tumor volume was measured over the 14 days of doxycycline treatment. Consistent with our cell-based studies, inactivation of PIK3CB resulted in significant tumor growth inhibition (T/C = 49%, P < 0.05) (Fig. 6A). To confirm successful target gene knockdown, representative tumor samples harvested from mice at the end of the study were analyzed by Western blot. Both the targeted protein, p110β, and its downstream effectors, phospho-AKT, phospho-PRAS40, phospho-S6, and phospho-GSK3β, were suppressed in doxycycline-treated but not in vehicle-treated tumor xenografts (Fig. 6B). Taken together, these findings strongly indicate that p110β is the critical PI3K isoform driving PI3K pathway activation and abnormal proliferation in PTEN-deficient tumors.

Discussion

The PI3K signaling pathway is one of the most frequently activated pathways in cancers (37). PIK3CA gain-of-function or PTEN loss-of-function mutations are the most frequent genetic alterations in this pathway. In this study we set out to determine which PI3K isoforms are most critical for growth and pathway signaling in cancer cells containing these different genetic lesions. Consistent with the analysis of somatic PIK3CA knockout cell lines (31), we found that depletion of PIK3CA using an inducible shRNA leads to a marked decrease in the phosphorylation of key p110α downstream targets and inhibits proliferation of the PIK3CA mutant colorectal cancer cell lines HCT116 and DLD1. In addition, PIK3CA knockdown also led to a dramatic reduction in downstream PI3K signaling and tumor growth inhibition in an in vivo PIK3CA mutant xenograft model. The inducible nature of our shRNA system allowed us to expand on previous work by demonstrating that PI3K signaling is important not only for the initiation but also for the maintenance of established colorectal tumor xenografts. Together, our in vivo results further validate p110α as a promising therapeutic target in PIK3CA mutant cancers.

The clinical observation that PIK3CA and PTEN mutations occur in almost all cancers in a mutually exclusive fashion (15–18), combined with the absence of somatic cancer mutations in PIK3CB or PIK3CD, provided strong genetic indication that the tumorigenic effects of PTEN loss may be mediated by p110α. Our study, however, revealed that knockdown of PIK3CA in PTEN-deficient cancer cell lines neither alters PI3K signaling nor has an effect on cell growth and survival. Based on these findings, we would predict that many PTEN-deficient cancers will not respond to a selective p110α inhibitor.

Our data clearly demonstrate that p110β is the critical lipid kinase that drives PI3K pathway activation, cell growth, and survival in PTEN-deficient cancer cell lines. This unexpected finding raises many important questions regarding the function of p110 isoforms in both normal and cancer cells. For instance, given the importance of p110β in PTEN-deficient cells, it is surprising that p110β, in stark contrast to p110α, does not seem to be mutated in human cancers.
(9) One possible explanation may be that p110β has significant activity in the absence of growth factor stimulation. Thus, in the absence of the PTEN lipid phosphatase activity, the unbalanced phosphorylation of PIP2 by p110β would result in aberrant activation of PI3K downstream effector pathways. In contrast, p110δ and p110γ have low constitutive activity and can be activated only upon growth factor stimulation. In this model, mutational activation of the normally inactive p110α would provide greater selective growth advantage to cancer cells than the incremental activation of an already active p110α. In addition, differences in the activity of regulatory subunits to control individual p110-isofrom activities may further limit any selective advantages gained from mutating p110α (38–40).

Although the dependency on p110β for both PI3K pathway signaling and growth in the panel of PTEN-deficient cell lines assessed in this study is very striking, it is conceivable that the requirement for p110β in PTEN-deficient cells is highly dependent on its genetic context. For example, in rare instances where PTEN loss-of-function mutations coexist with PIK3CA-activating mutations (19), as is the case in the ovarian cancer cell line A2780, down-regulation of p110α activity, but not of p110β activity, resulted in PI3K pathway inactivation and cell growth inhibition (Fig. 5). We favor the hypothesis that the 9-nucleotide deletion spanning the PTEN lipid phosphatase domain observed in A2780 cells generates a hypomorphic rather than null PTEN protein. Thus, the partially active PTEN protein allows additional selective advantage for the acquisition of PIK3CA mutations. In this setting, PIK3CA-activating mutations may be dominant to inactivating mutations in PTEN. Therefore, we speculate that p110β dependency may be most penetrant in cancers cells harboring PTEN-null alleles in the absence of PIK3CA mutations. This hypothesis remains to be tested in larger cancer cell panels. Taken together, these findings indicate that the genetic context in which inactivating mutations in PTEN are found is likely to dictate its dependency on individual Class IA PI3Ks.

In conclusion, our results have significant implications for the ongoing and future efforts to discover drugs targeting the PI3K pathway. Pan-Class IA PI3K inhibitors are expected to have the broadest clinical utility, because they are expected to retard growth of both PIK3CA mutant and PTEN-null cancers. However, the important functions of individual PI3K isoforms in normal tissue homeostasis raise concerns about dose-limiting on-target side effects (30). Isoform-selective drugs that target only the relevant oncogenic PI3K isoform hold great promise for circumventing unnecessary isoform-derived toxicities and thereby should provide a larger therapeutic window. In this light, our study provides a strong rationale for the development of p110β-specific inhibitors for the treatment of PTEN-deficient cancers. More generally, our findings further highlight the need to match thoughtfully the molecular and genetic signature of a particular cancer with the appropriate anti-PI3K therapy.

Materials and Methods

A detailed description of the Materials and Methods can be found in SI Materials and Methods.

Note. While this manuscript was under review, Jia, et al. (41) reported that p110β is essential to the transformed phenotype in a PTEN-null prostate cancer mouse model.

Acknowledgments. We thank Drs. William Sellers, Marion Dorsch, Christine Fritsch, Steve Fawwell, Carlos García-Echeverria (Novartis Institutes for BioMedical Research), and Thomas Roberts (Dana Farber Cancer Institutes) for fruitful discussions and critical reading of the manuscript.

Supporting Information

Wee et al. 10.1073/pnas.0802655105

SI Materials and Methods

Plasmid Construction and Mutagenesis. To generate shRNA-expressing plasmids, double-stranded oligos encoding the desired shRNA were cloned into single-vector inducible shRNA construct pLKO-Tet-On (Fig. S1). Human PIK3CB cDNA was provided by T. Roberts (Dana Farber Cancer Institute, Boston, MA) and was cloned into single-vector inducible expression construct pLKO-TREX-HA (Fig. S1). Lentiviruses were generated as described in reference 1. Target cell lines were infected with lentiviral inducible RNAi or expression constructs at MOI = 1 and selected in 1 μg/ml puromycin-containing growth medium until no untransduced cells remained.

The following double-stranded oligos were inserted between the AgeI/EcoRI restriction sites of pLKO-Tet-On to generate inducible RNAi: Control:

- sense: 5’ CCGGGTGACCTTGAAAGTACTTCCTGCAGATAGTCTTCAAGAGCTCAGCTTTTT3’; antisense: 5’ AATTTAAAGGTGACCTTTGAAAGTACTTCCTGCAGATAGTCTTCAAGAGCTCAGCTTTTT3’

- PIK3CB: sense: 5’ CCGGGCCAGCATCTCATGTTAGACTCGAGTCTTAATCTCATGAGTGATCGTTC GACATCACCTCGAGGTATTTTT3’; antisense: 5’ AATTTAAAGGTGACCTTTGAAAGTACTTCCTGCAGATAGTCTTCAAGAGCTCAGCTTTTT3’

- PIK3CB #2074: sense: 5’ CCGGGTGACCTTGAAAGTACTTCCTGCAGATAGTCTTCAAGAGCTCAGCTTTTT3’; antisense: 5’ AATTTAAAGGTGACCTTTGAAAGTACTTCCTGCAGATAGTCTTCAAGAGCTCAGCTTTTT3’

PIK3CB rescue cDNA constructs were created by replacing 6 synonymous nucleotides in the region targeted by PIK3CB shRNA#1462 using a site-directed mutagenesis kit (Stratagene). PIK3CB aspartic acid residue 937 was replaced by alanine to create a lipid kinase-inactive shRNA rescue construct. The wild-type and lipid kinase-inactive PIK3CB could not be targeted for PIK3CB shRNA knockdown as determined by Taqman quantitative PCR (Applied Biosystems) and Western blot analysis. PTEN siRNA was purchased from Dharmacon (#L-003023-00) and transfected at 50 nM according to protocols provided by Dharmacon.

Cell Culture, Proliferation, Colony Formation, Soft Agar Assays, and Compound Treatment. All cell lines were purchased from ATCC. Untransformed (wild-type) cell lines were maintained in DMEM (Invitrogen) supplemented with 10% (vol/vol) FBS (Invitrogen). All shRNA- or p110β-expressing stable cell lines were grown in DMEM supplemented with 10% Tet-approved FBS (Clontech) in the presence of appropriate antibiotic selection, shRNA or cDNA expression was induced by culturing cells in the presence of 10–100 ng/ml of doxycycline (Sigma). Proliferation, colony formation, and soft agar assays were carried out as described in ref. 1.

Western Blot Analysis. Cells were scraped together in cold PBS, briefly centrifuged and lysed in 50 mM Tris-HCl, 1% Nonidet P-40, 120 mM NaCl, 25 mM NaF, 40 mM beta-glycerol phosphate, and 1X Halt Protease inhibitor mixture (Pierce #78430). Fifty μg of protein was separated on a SDS/PAGE followed by protein transfer to nitrocellulose membrane. The following primary antibodies from Cell Signaling were used in this study: anti-p110α (#4255), phospho-AKT (#9271 and #4056), total AKT (#9272), phospho-FK/FKHR1L (#9464), phospho-p70 S6 kinase (#9202), phospho-GSK3β (#9331), and phospho-pS6 (#2448). Anti-GAPDH was purchased from Novus Biologicals, anti-TetR from MoBi Tec (#TET0102), and anti-Pras40 from Invitrogen (#441100G). To investigate p110α knockdown in vivo, tumor tissue was snap-frozen in liquid nitrogen and mechanically pulverized. Tissue powder was reconstituted in lysis buffer as described previously and was processed for Western blot analysis as described.

Quantitative RT-PCR. mRNA levels were measured using TaqMAN Gene Expression Assays on an ABI PRISM 7900 HT Sequence Detection System supplied by Applied Biosystems. RNA isolation was performed using the Qiagen TurboCapture mRNA kit (#72232) and followed by cDNA synthesis (iScript; Bio-Rad). All probes (PIK3CA #00180679; PIK3CB #00178872; PIK3CB #00192399) were purchased from Applied Biosystems. VIC-MGB B-Actin primers (Applied Biosystems) were used in each reaction to co-amplify the actin transcript and as an internal control. All experiments were performed in triplicate and were normalized to β-actin levels. Relative mRNA expression is given by the formula 2−Δ(ΔCT) where C(T) (cycle count) is the threshold cycle value.

Compound Treatment. To determine impact on pathway signaling, cells were grown to 80% confluency and treated with 2 μM of compound for 30 min. Cells were harvested for Western blot analysis as described previously. To determine impact on growth, PC3 cells were seeded at 2000 cells per well of a 6-well dish and treated with compound at either 1 μM or 5 μM. Compound-containing medium was exchanged every 72 h. Cells were fixed and stained with crystal violet after 15 days of growth.

Tumor Xenograft Studies. All experiments involving mice were carried out in strict accordance with institutional and local government guidelines on handling of laboratory animals. Efficacy study of inducible PIK3CA knockdown in HCT116 and PC3 tumor xenografts. Stable cell lines used in this study have been shown to be free of mycoplasma and viral contamination. A maximum of 10 male Harlan nude mice were kept under sterile conditions (type III cage, in an Optimal Hygienic Conditions zone) with free access to food and water. PC3- and HCT116-(type III cage, in an Optimal Hygienic Conditions zone) xenografts were established by s.c. injection of cells (2×106 cells in 100 μl PBS). The resulting tumors (700–1000 mm3) were passaged in vivo at least 3 times before experimentation. Tumor fragments of about 25 mg were implanted s.c. into the left flank of male animals with a 13-gauge trocar needle under Forene (Abbott) anesthesia. Treatments were initiated when mean tumor volume in each group (n = 6–8) reached at least 100 mm3. Animals received either vehicle (5% dextrose in drinking water, ad libitum) or doxycycline lyrate (25 mg/kg per day by oral gavage or as 2 mg/ml in 5% dextrose in drinking water, ad libitum) for the duration of the study. Tumor volume and body weight were measured twice per week. Tumor volume was determined by using calipers for measurement of the longest (considered as Length) and shortest (considered as Diameter) dimensions of each tumor and according to the formula: Tumor Volume = Length × Diameter2 × π/6. At termination of the study, tumor tissue was collected and snap-frozen in liquid nitrogen for Western blot analysis. Antitumor activity is expressed as the mean increase of tumor volumes of treated animals divided by...
the mean increase of tumor volumes of control animals multiplied by 100 (T/C%). Data are presented as means ± SEM. For tumor size, comparisons between groups and the vehicle water control group were done using either 1-way ANOVA or ANOVA on ranks followed by Dunnett’s tests (when data were not normally distributed). For all tests, the level of significance was set at \( P < 0.05 \). Calculations were performed using SigmaStat version 2.03 (Jandel Scientific).

**Efficacy study of inducible PIK3CB knockdown in PC3 xenografts.** PC3 cells engineered to express inducible shRNA against PIK3CA were cultured in McCoy’s 5A modified medium supplemented with 10% Tet-free FBS before implantation. Cells were free of mycoplasma and viral contamination. Mice (6–8 weeks old) were inoculated s.c. with \( 1 \times 10^6 \) cells in the right dorsal axillary region. Fourteen days after implantation, animals were sorted randomly into treatment groups (\( n = 8 \)) based on tumor volume (mean tumor volume = 100 mm\(^3\)). Animals received vehicle (5% dextrose, 10 ml/kg per day by mouth) or doxycycline hyclate (25 mg/kg per day by oral gavage) for the duration of the study (14 days). Animals were callipered twice weekly to monitor the effect of treatment on tumor growth. Changes in body weight also were monitored and recorded. At termination of the study, tumor tissue was collected and snap-frozen in liquid nitrogen for Western blot analysis. Tumor volume calculations and statistical analysis were carried out as described above.

Fig. S1. Schematic of pLKO-Tet-On and pLKO-TREX-HA vectors used in this study.
Fig. S2. Characterization of cell lines used in this study. (A) Cell lysates were harvested from respective cell lines and immunoblotted for PTEN protein. Endogenous GAPDH is shown as a loading control. (B) Transcript levels of either PIK3CA or PIK3CB were determined for each cell line by Taqman RT-PCR. (C and D) Knockdown efficiency of PIK3CA or PIK3CB by the respective targeting shRNA in the presence of doxycycline was assessed by Taqman RT-PCR.
Fig. S3. Additional PIK3CB targeting shRNA (#2074) affects both (A) PIK3CB transcript level and (B) growth in the presence of doxycycline (DOX).
Fig. S4. Expression of PIK3CB rescue constructs in PC3 cells containing control shRNA does not produce a dominant negative effect. DOX = doxycycline; KD = kinase-dead. (A) PIK3CB transcript levels in the presence of the respective rescue constructs were determined by Taqman RT-PCR. (B and C) Expression of the respective rescue construct does not affect PI (3)K pathway signaling, as determined by Western analysis, nor growth, as determined in a foci formation assay.
Fig. S5.  p110β-Selective compounds specifically affect signaling and growth in PTEN-deficient cells. (A) DLD1, HCT116, PC3, BT549, and U87MG cells plated in a 6-well dish were treated with DMSO control, PAN (BEZ235), β#1 (TGX221), or δ (IC87714) inhibitors for 30 min at 2 μM. Cell lysates subsequently were harvested for Western blot analysis. (B) PC3 cells were cultured in a 6-well dish for 14 days in the presence of DMSO control or 2 p110β compounds, TGX221 (β#1) or TGX256 (β#2), at 1 μM or 5 μM concentrations. Medium and compounds were replenished every 72 h. Impact on colony formation was visualized by crystal violet staining. (C) Effect on PI (3)K pathway signaling in PC3 cells treated with DMSO control or the respective p110β compound at 1 μM or 5 μM after 1 h or 72 h of continuous treatment was determined by Western analysis. Endogenous GAPDH is shown as a loading control.

Wee et al.  www.pnas.org/cgi/content/short/0802655105
Fig. S6. A2780 Cells are dependent on p110α. Dox = doxycycline. (A) Knockdown efficiency of PIK3CA or PIK3CB was assessed by Taqman RT-PCR after 72 h of doxycycline treatment. (B) Impact of PIK3CA silencing on pathway signaling was determined by Western analysis. (C) Proliferation of A2780 in the presence or absence of doxycycline and the respective shRNA were monitored by CellTiterGlo for 1 week. Fold change in growth is presented. (D) Similarly treated cells were cultured in a 6-well dish at low density and monitored for growth over a 10-day period. Foci formation was visualized by crystal violet staining.